cellectis
Cellectis Plant Sciences annonce la signature d’un partenariat stratégique avec SESVanderHave pour améliorer la betterave sucrière
- 31/01/2012 |
- 10:35 am |
- valerie
Saint-Paul (Minnesota, Etats-Unis), le 31 janvier 2012 – Cellectis plant sciences, spécialiste de l’ingénierie du génome des plantes et filiale de Cellectis (Alternext : ALCLS), annonce aujourd’hui la signature avec SESVanderHave, un des leaders mondiaux de l’industrie des semences de betterave sucrière, d’un accord commercial et de recherche pour l’utilisation des technologies de Cellectis.
Changes in the Group’s Scientific Division and appointment of the CEO of Cellectis Plant Sciences
- 30/01/2012 |
- 7:03 pm |
- valerie
Paris, January 30th, 2012 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, is announcing the operational withdrawal of Frédéric Pâques, who has joined the Group’s Scientific Advisory Board, as well as three appointments in its Scientific Division: Jean-Charles Epinat as Chief Technology Officer, Philippe Duchâteau as Chief Scientific Officer, and Frédéric Cédrone as Platform Director. Alongside this, Luc Mathis has been appointed CEO of Cellectis Plant Sciences, a Cellectis subsidiary.
Cellectis lance un partenariat avec Total dans la recherche exploratoire sur les substituts aux produits pétroliers à partir de microalgues
- 09/01/2012 |
- 3:03 pm |
- valerie
Paris, le 9 janvier 2012 – Cellectis (Alternext : ALCLS), le spécialiste français de l’ingénierie des génomes, annonce aujourd’hui la signature d’un accord avec Total portant sur le développement de substituts pétroliers dérivés de microalgues. Le programme de recherche comprend une première phase d’une durée d’un an qui pourrait être suivie d’une seconde phase de deux à trois ans.
Cellectis plant sciences and Bayer CropScience strengthen genome engineering partnership
- 04/01/2012 |
- 11:30 am |
- valerie
Saint Paul (Minnesota, USA), January 3, 2012 – Cellectis plant sciences, the plant genome engineering company and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has signed a research and commercial agreement with Bayer CropScience AG, a subsidiary of Bayer AG and a leader in crop protection, non-agricultural pest control, seeds and plant biotechnology, to collaborate on the use of meganucleases in plants. The aim of this agreement is to develop commercial products for the agricultural seed markets using new breeding techniques such as gene stacking and targeted mutagenesis, two approaches key to the development of agricultural products.
Cellectis signs a license agreement under patents covering uses of homologous recombination with global pharmaceutical company
- 06/12/2011 |
- 11:03 am |
- valerie
Paris, December 5th, 2011 -Cellectis, the genome engineering specialist (Alternext: ALCLS), is announcing that it has signed a license agreement with Novartis for the patents of the family WO 90/11354 covering certain uses of homologous recombination. This technology, which belongs to the Pasteur Institute and for which Cellectis owns exclusive rights, makes it possible to introduce new characteristics into genomes.
Cellectis announces the final completion of the acquisition of Cellartis and €50 million financing round reserved for the FSI and Mr. Pierre Bastid.
- 04/11/2011 |
- 11:09 am |
- valerie
Paris, Friday November 4, 2011 -Cellectis (Alternext: ALCLS) announces the final completion of the acquisition of Cellartis, the Swedish company and European market leader for stem cell-based in vitro R&D tools, and the resulting issue of 1,933,333 Cellectis shares to the former Cellartis’ shareholders, as well as the final completion of the issue of 6,250,000 convertible bonds for €50 million, evenly subscribed by the French strategic investment fund (FSI) and Mr. Pierre Bastid.
(English) Cellectis shareholders approve the acquisition of Cellartis.
- 02/11/2011 |
- 11:44 am |
- valerie
(English) Cellectis (Alternext: ALCLS) announces that the shareholders’ meeting held on Friday the 28th of October approved (i) the acquisition of Cellartis, the Swedish company and European market leader for stem cell-based in vitro R&D tools, (ii) a €50 million round of financing reserved for two new investors, the French strategic investment fund (FSI) and Mr. Pierre Bastid, to finance this acquisition and accelerate Cellectis growth strategy, and (iii) the allocation of free share purchase warrants to the existing shareholders
(English) Appointment of Philippe Valachs as Cellectis’ General Secretary
- 24/10/2011 |
- 8:57 am |
- valerie
(English) Paris, October 24th, 2011 – Cellectis (Alternext: ALCLS) Cellectis, the genome engineering specialist, is announcing the appointment of Philippe Valachs as Company Secretary.
Cellectis: 2011 half-year earnings
- 07/10/2011 |
- 2:05 pm |
- valerie
Paris, October 6, 2011 (5.45 pm CET) – Cellectis (Alternext: ALCLS), the genome engineering specialist, is releasing its condensed consolidated accounts for the first half of 2011, and an update on its activities.
CELLECTIS ISSUES STATEMENT REGARDING PATENT SUITS ON MEGANUCLEASE TECHNOLOGY
- 04/10/2011 |
- 9:24 am |
- valerie
Paris (France), October 3, 2011: Cellectis SA (Alternext: ALCLS), the French genome engineering company, provided an update today regarding its recent patent litigations against Precision Biosciences, Inc. (“Precision”).
PDF 
